PANCREAZE is a combination of porcine-derived lipases, proteases, amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

37,000 LIPASE UNIT DOSE AVAILABLE.

Try the Pancreaze dosing calculator.

37,000 LIPASE UNIT DOSE AVAILABLE.

Try the Pancreaze dosing calculator.

Dosing and Administration

Is your patient a candidate for PANCREAZE 37,000?¹

PANCREAZE 37,000 can be a convenient, appropriate dose for many EPI patients — minimizing the number of capsules they take daily.

PANCREAZE 37,000 may not be appropriate for all patients. PANCREAZE is also available in 2,600, 4,200, 10,500, 16,800 and 21,000 lipase unit capsules.

A patient’s dose should be individualized based on age, weight, clinical symptoms, degree of steatorrhea and fat content of their diet.
Mealtime dose can vary based on the fat content and volume of the meal ingested.
Usually, half of the prescribed dose for an individualized full meal should be given with each snack.

The following guide highlights the minimum and maximum range of 37,000 unit capsules by patient weight range:

Patient
Weight (lbs)

Minimum Dose
Per Snack

Minimum Dose
Per Meal

Maximum Dose
Per Meal

110 to 130

3 pills

131 to 163

4 pills

164 to 195

5 pills

196 to 228

6 pills

≥ 229

7 pills

This chart is intended as a guide only. Capsules shown are not actual size.
PANCREAZE should be initiated at the lowest recommended dose and gradually increased.
For children 4 years and older and adults, dosing should begin with 500 lipase units/kg of body weight per meal up to a maximum of 2,500 lipase units/kg of body weight per meal.
The number of capsules represent nearest pill count within the recommended range.
Patients weighing <110 lbs may require a lower lipase unit starting dose.
Patients weighing >230 lbs may require a higher lipase unit starting dose and have a higher per-meal maximum dose.
PANCREAZE dosing is consistent with Cystic Fibrosis Foundation recommendations.
PANCREAZE is dosed by lipase units and is not interchangeable with any other pancrelipase product.
Doses greater than 6,000 lipase units/kg of body weight per meal have been associated with colonic strictures, indicative of ﬁbrosing colonopathy, in children with cystic ﬁbrosis less than 12 years of age.

PANCREAZE 37,000 Prescribing Scenario¹

PANCREAZE® (pancrelipase) 37,000 lipase units. 2 capsules p.o. during each meal. 1 capsule p.o. during each snack. 30-day total: 240 capsules. Note: Take during every meal and snack.

Prescribe PANCREAZE for both meals and snacks

175lb patient’s dose titrated to provide 1,000 lipase units/kg/meal based on symptoms and diet (79,365 USP lipase units per meal).
Mealtime dose can vary based on symptoms and the fat content and volume of the meal ingested. Please review the appropriate doses for your patient’s individual dietary needs. See the dosing chart above.
Prescribe PANCREAZE for both meals and snacks.

Review the data and learn how PANCREAZE can improve EPI symptoms.

REVIEW THE DATA

This tool can help with your PANCREAZE dosing considerations.

USE THE CALCULATOR

PANCREAZE 37,000 can be a convenient, appropriate dose for many EPI patients.

VIEW DOSING GUIDE

Learn more and access the following:

PANCREAZE HCP Resource Center

Request materials, a rep call, or order samples of the 37,000 unit dose

VISIT THE RESOURCE CENTER

Indication

PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth.

There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE. Although it has never been reported, it may be possible for a person to get a viral infection from taking pancreatic enzyme products that come from pigs.

Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Most common adverse reactions are: abdominal pain, flatulence, diarrhea, abnormal feces, and fatigue.

PANCREAZE is not interchangeable with any other pancrelipase products.

Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.

Please read the PANCREAZE Medication Guide and PANCREAZE Product Information.

References: 1. PANCREAZE Full Prescribing Information. Campbell, CA: VIVUS LLC; 2022. 2. Trapnell BC, et al. Efficacy and safety of PANCREAZE for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 011;10(5):350-356. 3. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55-73. 4. Whitcomb, DC, Buchner, AM, Forsmark, CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insuﬃciency: Expert Review. Gastroenterology. 2023;165:1292–1301. 5. Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract. 2018;72:e13066. 6. Crohns and Colitis Foundation (n.d). IBS vs IBD. Retrieved from https:/www.crohnscolitisfoundation.org/what-is-ibd/ibs-vs-ibd 7. Crohns and Colitis Foundation (n.d). Signs and Symptoms of Crohn’s Disease. Retrieved from https://www.crohnscolitisfoundation.org/what-is-crohns-disease/symptoms 8. Kaitha S, Bashir M, Ali T. Iron deﬁciency anemia in inﬂammatory bowel disease. World J Gastrointest Pathophysiol. 2015 August 15; 6(3): 62-72. 9. Perler et al. Presenting symptoms in inﬂammatory bowel disease: descriptive analysis of a community-based inception cohort. BMC Gastroenterology (2019); 19:47. 10. Fousekis FS, Theopistos VI, Katsanos KH, Christodoulou DK. Pancreatic Involvement in Inflammatory Bowel Disease: A Review. J Clin Med Res. 2018;10(10):743-751. 11. Crohns and Colitis Foundation (n.d). Signs and Symptoms of Ulcerative Colitis. Retrieved from https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis/symptoms 12. Freeman HJ. Iron deficiency anemia in celiac disease. World J Gastroenterol. 2015 August 21; 21(31):9233-9238. 13. Zaidel O, Lin HC. Uninvited Guests: The Impact of Small Intestinal Bacterial Overgrowth on Nutritional Status. Practical Gastroenterology. 2013; Nutrition Issues in Gastroenterology, Series #7: 23-34. 14. Struyvenberg MR, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency – Breaking the myths. BMC Med. 2017; 15(1): 29. 15. Al-Kaade S (2020, February 3). What causes anemia in exocrine pancreatic insufficiency (EPI)? Medscape. Retrieved from https://www.medscape.com/answers/2121028-18736/what-causes-anemia-in-exocrinepancreatic-insufficiency-epi 16. Vujasinovic M, Valente R, Thorell A, Rutkowski W, Haas SL, Arnelo U, Martin L, Löhr JM. Pancreatic Exocrine Insufficiency after Bariatric Surgery. Nutrients. 2017 Nov 13;9(11):1241. 17. Uribarri-Gonzalez L, Nieto-García L, Martis-Sueiro A, Dominguez-Muñoz JE. Exocrine pancreatic function and dynamic of digestion after restrictive and malabsorptive bariatric surgery: a prospective, cross-sectional, and comparative study. Surg Obes Relat Dis. 2021 Oct;17(10):1766-1772. 18. The National Pancreas Foundation (n.d.). Exocrine Pancreatic Insufficiency (EPI). Retrieved from https://pancreasfoundation.org/patient-information/ailments-pancreas/exocrine-pancreatic-insufficiency-epi/ 19. Cystic Fibrosis Foundation. (n.d.). Phthalates. Retrieved from https://www.cff.org/phthalates. 20. CREON^® Full Prescribing Information. Chicago, IL: Abvie, Inc; 2023. 21. PERTZYE^® Full Prescribing Information. Bethlehem, PA: Digestive Care, Inc; 2022. 22. VIOKACE™ Full Prescribing Information. Birmingham, AL: Allergan USA, Inc; 2012. 23. ZENPEP^® Full Prescribing Information. Bridgewater, NJ: Aimmune Therapeutics, Inc; 2023. 24. Borowitz DS, et al. the Consensus Committee. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr. 1995; 127:681-84.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

VIEW ALL +